Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hutchison China Meditech

15.60
+1.7112.31%
Volume:108.83K
Turnover:1.68M
Market Cap:2.67B
PE:78.00
High:15.85
Open:15.12
Low:15.08
Close:13.89
Loading ...

AI Becoming Essential to HCM, ISG Says

Business Wire
·
21 Mar

Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

MT Newswires Live
·
21 Mar

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
21 Mar

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

Business Wire
·
21 Mar

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
20 Mar

Cytokinetics announces launch of EARTH-HCM

TIPRANKS
·
20 Mar

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire
·
20 Mar

Press Release: Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Dow Jones
·
20 Mar

Oracle Helps Customers Boost Employee Engagement with Strategic Communications and Internal Events

PR Newswire
·
20 Mar

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

GuruFocus.com
·
20 Mar

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Benzinga
·
20 Mar

Stock Track | Hutchison China Meditech Soars 7.36% on Strong 2025 Outlook and Positive Clinical Trial Results

Stock Track
·
19 Mar

Stock Track | Hutchison China Meditech Soars 5.95% Pre-market on Strong 2025 Guidance and Positive Clinical Trial Results

Stock Track
·
19 Mar

Sector Update: Health Care Stocks Steady to Higher Pre-Bell Wednesday

MT Newswires Live
·
19 Mar

Here’s What Lifted Paycom Software (PAYC) Stock up More Than 20%

Insider Monkey
·
19 Mar

Hutchmed's 2024 Earnings, Revenue Fall

MT Newswires Live
·
19 Mar

Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M

TIPRANKS
·
19 Mar

Hutchmed reports FY24 EPS 22c vs. 59c last year

TIPRANKS
·
19 Mar

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

Benzinga
·
19 Mar

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

Benzinga
·
19 Mar